ABL Diagnostics S.A. (Euronext: ABLD – ISIN: FR001400AHX6) informs the market that the non-binding Letter of Intent entered into between ProPhase Labs, Inc. and Advanced Biological Laboratories S.A. ( ...

ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight. We’re ...

UNIONDALE, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics and consumer products company, today announced that ...

An update from Prophase Labs ( (PRPH) ) is now available.

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The ...

Proposed transaction aims to deliver near-term value for ProPhase shareholders, long-term growth for ABL, and create a global, innovation-driven company. Company to hold a virtual conference call ...

Prophase Labs ((PRPH)) has held its Q2 earnings call. Read on for the main highlights of the call. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and ...

Access the complete ProPhase Labs Research Report, along with 1,400+ other detailed company analyses, exclusively on InvestingPro. In other recent news, ProPhase Labs Inc. has reported its ...

ProPhase Labs, Inc. (OTC: PRPH) ('ProPhase” or the 'Company”) is pleased to invite investors to a webinar on Tuesday, February 3, 2026, at 4:15 p.m. ET.

ProPhase Labs is embarking on a significant financial restructuring, pivoting its strategy to bolster its balance sheet. The company has formally initiated the sale process for its esophageal cancer ...

GARDEN CITY, NY, Aug. 11, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH) (“ProPhase” or the “Company”), a diversified medical science and technology company, today announces the ...